Mode
Text Size
Log in / Sign up
N/A N=276 Randomized Treatment

Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population

Presbyopia

Enrolled (actual)
276
Serious AEs
0.0%
Results posted
Jun 2016
Primary outcome: Primary: Binocular Distance Visual Acuity (LogMAR) — -0.068; -0.058; -0.109; -0.107 LogMAR

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
etafilcon A (Device); lotrafilcon B (Device)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Johnson & Johnson Vision Care, Inc.
Primary completion
Feb 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Binocular Distance Visual Acuity (LogMAR)
-0.068; -0.058; -0.109; -0.107
PRIMARY
Binocular Near Visual Acuity (logMAR)
0.063; 0.082; 0.048; 0.043
PRIMARY
Percentage of Eyes With Corneal Staining Grade 3 or Higher
0.0; 0.0; 0.0; 0.0
PRIMARY
Percentage of Eyes With Limbal Conjunctival Redness Grade 3 or Higher
0.0; 0.0; 0.0; 0.0
PRIMARY
Percentage of Eyes With Bulbar Conjunctival Redness Grade 3 or Higher
0.0; 0.0; 0.0; 0.0
PRIMARY
CLUE Overall Quality of Vision Using the Contact Lens User Experience (CLUE)TM Questionnaire
46.48; 44.79; 47.74; 50.17

Summary

The objective of this study is to evaluate the performance of a novel multifocal lens system.

Eligibility Criteria

Inclusion Criteria

  • Subjects must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Subjects must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  • Subjects must be between 40 and 70 years of age.
  • Subjects' spherical equivalent distance refraction must be in the range of -3.75 to +3.75 in each eye.
  • Subjects' refractive cylinder must be less than or equal to 0.75D in each eye.
  • Subjects' ADD power must be in the range of +0.75 to +2.50D in each eye.
  • Subjects' must have the best corrected visual acuity of 20/20-3 or better in each eye.
  • Subjects' should own a wearable pair of spectacles.
  • Subjects' must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month or more duration).
  • Subjects' must respond positively to at least on symptom on the "Presbyopis Symptoms Questionnaire" or already be wearing a presbyopic contact lens correction (e.g. reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.).

Exclusion Criteria

  • Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
  • Any previous intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.)
  • Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) which may contraindicate contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • History of binocular vision abnormality or strabismus.
  • Any infectious disease (e.g. hepatitis, tuberculosis) or contagious immunosuppressive disease (e.g. HIV).
  • History of diabetes.
  • Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01763047). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search